Quick Summary
- Veeva shares climbed approximately 12% following a fourth-quarter earnings surprise, posting EPS of $2.06 versus the anticipated $1.94.
- Quarterly revenue reached $836 million, reflecting 16% growth year-over-year and surpassing the $811 million analyst projection.
- First-quarter outlook calls for EPS of $2.13–$2.14 and revenue of $855–$858 million, both exceeding Street expectations.
- Full-year fiscal 2027 revenue guidance of $3.585–$3.6 billion tops the $3.56 billion consensus estimate.
- The company disclosed that ten of the world’s top 20 biopharma firms have adopted its Vault CRM solution.
Veeva Systems entered 2026 on shaky ground, with shares declining 16% prior to the quarterly report. Wednesday evening’s announcement dramatically shifted sentiment.
Fourth-quarter performance significantly exceeded analyst projections. The company delivered adjusted earnings per share of $2.06, comfortably surpassing the $1.94 consensus figure. Quarterly revenue climbed 16% from the prior year to $836 million, outpacing the $811 million forecast.
Investors reacted swiftly. Shares of VEEV jumped approximately 12% when markets opened Thursday morning.
The positive momentum extended beyond historical performance. Management’s forward-looking projections provided additional confidence for shareholders.
For the first quarter, Veeva outlined EPS expectations of $2.13 to $2.14, surpassing Wall Street’s $2.10 projection. The revenue forecast of $855 to $858 million also exceeded the $853 million consensus.
Looking at the complete fiscal year 2027, management anticipates revenue between $3.585 and $3.6 billion. This guidance beats the Street consensus of $3.56 billion. Non-GAAP EPS guidance of $8.85 similarly topped analyst expectations of $8.60.
Billings projections captured significant analyst attention. KeyBanc’s Scott Schoenhaus highlighted the “healthy billings guidance” as a valuation support during intense selling pressure across software stocks.
Schoenhaus, maintaining a Sector Weight rating on VEEV, suggested the results should alleviate worries surrounding the broader software sector downturn linked to emerging AI coding technologies.
Major Pharma Adoption
A particularly noteworthy disclosure emerged from the quarterly report. Veeva revealed that 10 of the globe’s top 20 biopharmaceutical corporations have now adopted its Vault CRM platform.
This represents tangible evidence of traction in a critical product segment.
Vault CRM addresses the unique needs of life sciences organizations, managing regulatory compliance and operational processes that generic CRM solutions inadequately support. Securing commitments from major pharmaceutical players requires significant time — making these wins particularly meaningful.
Veeva’s financial metrics support the expansion narrative. The company maintains a net margin of 27.93% alongside a gross margin of 75.67%. Its current ratio stands at 7.53 while the debt-to-equity ratio registers just 0.01.
By any standard, that represents an exceptionally solid balance sheet.
Assessing Valuation
Prior to the earnings-driven surge, VEEV’s P/E ratio of 36.67 hovered near its decade-low point. The P/S ratio of 10.25 and P/B ratio of 4.4 similarly tracked near multi-year lows.
Wall Street analysts maintained a consensus price target of $292.17 — substantially above the stock’s pre-earnings trading level.
Institutional investors hold 86.51% of outstanding shares, demonstrating significant confidence from major investment firms. Company insiders own 7.59%, with 1,000 shares sold by insiders over the recent three-month period.
The firm’s three-year revenue compound growth rate measures 13.4%, while its Altman Z-Score of 19.88 indicates robust financial stability.
By Thursday morning, VEEV traded near $201.33, climbing from approximately $188 before the earnings announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
